4-<(4-methoxyphenyl)phenylmethyl>piperidine | 69031-32-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-<(4-methoxyphenyl)phenylmethyl>piperidine
• 英文别名: 4-[(4-methoxyphenyl)phenylmethyl]piperidine；4-[(4-Methoxyphenyl)-phenylmethyl]piperidine
• CAS: 69031-32-9
• 化学式: C₁₉H₂₃NO
• 分子量: 281.398
• InChiKey: JMWLINDEPHCQPF-UHFFFAOYSA-N

物化性质

• 沸点：
  427.7±33.0 °C(Predicted)
• 密度：
  1.047±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-<(4-methoxyphenyl)phenylmethyl>piperidine 在 光气 、 乙酸酐 、 potassium carbonate 、 三乙胺 作用下， 反应 4.0h， 生成 4-<(4-methoxyphenyl)phenylmethyl>-1-<(octylimino)methyl>piperidine
  参考文献：
  名称：

  Antisecretory activity of human, dog, and rat metabolites of fenoctimine

  摘要：

  Fenoctimine (1a), a nonanticholinergic inhibitor of gastric acid secretion in dogs and rats, was evaluated as a gastric antisecretory agent in humans. In humans it exhibited weak antisecretory activity and caused anticholinergic-like side effects such as dry mouth and nasal passages. Studies of the metabolic fate of fenoctimine in humans, dogs, and rats provided structures of the resultant metabolites. These were synthesized and tested for antisecretory and anticholinergic activity. The human metabolites were all less active than fenoctimine as antisecretory agents, and some displayed significant anticholinergic activity. These results suggest that the unexpectedly weak effect of fenoctimine as a gastric antisecretory agent in humans, as well as anticholinergic effects, may be due to its extensive metabolism, which is different from that seen in dog and rat.

  DOI：

  10.1021/jm00388a025

文献信息

• <i>In vivo</i>biotransformation of fenoctimine in rat, dog and man
  作者：W.-N. Wu、J. F. Hills、S. Y. Chang

  DOI：10.3109/00498259409038672

  日期：1994.1

  1. The metabolism of fenoctimine (Fn) was studied in rat, dog and man following administration of C-14-Fn sulphate.2. Seventeen Fn metabolites were isolated by hplc and tie from rat bile, dog bile, dog urine, human urine, human faecal extracts, and human plasma and identified using nmr and MS.3. The identified metabolites accounted for 75% of total radioactivity in rat bile, 80% in dog bile, and 40% in dog urine samples. In man, 90% of the urinary, 70% of the faecal, and > 50% of the plasma total radioactivity were identified.4. Three major pathways for Fn metabolism were proposed. These pathways involved imino-bond cleavage, aromatic hydroxylation and oxidation of the aliphatic chain.5. The imino-bond cleavage pathway was dominant in all species. However, the other two pathways differed in quantitative importance among the species studied.6. The aromatic hydroxylation pathway appeared to be the most important means of biotransformation of Fn in dog since all but two of the metabolites were formed by this route.7. The aliphatic oxidation pathway appeared to be important to the biotransformation of Fn in man and produced three major metabolites.
• SCOTT M. K.; JACOBY H. I.; BONFILIO A. C.; CORCORAN T. W.; LOPEZ I. S., J. MED. CHEM., 30,(1987) N 5, 894-899
  作者：SCOTT M. K.、 JACOBY H. I.、 BONFILIO A. C.、 CORCORAN T. W.、 LOPEZ I. S.

  DOI：——

  日期：——
• NEW HETEROCYCLIC COMPOUNDS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3717477B1

  公开（公告）日：2022-07-20
• HETEROCYCLIC COMPOUNDS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20200392125A1

  公开（公告）日：2020-12-17

  The invention provides new heterocyclic compounds having the general formula (IA) wherein A, L, X, Y, m, n, R 1 and R 2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
• US4105849A
  申请人：——

  公开号：US4105849A

  公开（公告）日：1978-08-08